HK Inno.N out-licenses GERD drug K-CAB to US pharma company Deal is worth $540 million including $2.5 million upfront payment
Translated by Ryu Ho-joung 공개 2021-12-27 08:12:25
이 기사는 2021년 12월 27일 08:13 thebell 에 표출된 기사입니다.
South Korea’s HK inno.N singed an out-licensing deal worth $540 million with Braintree Laboratories to commercialize its gastroesophageal reflux disease (GERD) treatment K-CAB (tegoprazan) in North America, the company announced on Thursday.Braintree Laboratories is a subsidiary of Sebela Pharmaceuticals, a US specialty pharmaceutical company specializing in gastrointestinal health. The agreement marks the largest-ever out-licensing deal by the South Korean healthcare company to date.
HK inno.N will receive an upfront cash payment of $2.5 million – or only 0.5% of the total deal value – seemingly a small amount given 100 billion won ($84 million) of out-of-hospital prescription revenue expected to be generated by the drug this year in the domestic market.
The terms of the deal appear to reflect the US GERD drug market which is worth 20 trillion won a year, industry watchers said. The market is currently dominated by proton pump inhibitor (PPI) therapy. But many expect potassium-competitive acid blocker (P-CAB) drugs, like K-CAB, to become an alternative to PPIs as they offer higher efficacy and easier dosing.
There is no P-CAB drug launched in the US. Other pharmaceutical companies developing P-CABs include Japan’s Takeda Pharmaceutical, which out-licensed its P-CAB drug vonoprazan to Phathom Pharmaceuticals to commercialize it in the US.
In October this year, Phathom announced the topline results for the phase 3 clinical trial of vonoprazan, widening a gap with K-CAB which received approval for the phase 1 clinical trial from the US Food and Drug Administration in 2020.
Phathom plans to submit an application with the FDA in 2022 seeking approval for marketing in the US, raising expectations that its vonoprazan product could be first in class.
“P-CAB drugs are generally more expensive than PPIs, and this disadvantage should be overcome by showing that they can provide much higher efficacy,” an industry insider said.
Apart from the $2.5 million upfront payment, HK inno.N will receive $537.5 million in future milestone payments plus tiered royalties for commercialization. Development costs for the clinical trial in the US will be borne by Braintree Laboratories.
“With this licensing deal with Braintree Laboratories, we will continue efforts such as changing dosage forms to expand the market share of our P-CAB drug,” an official at HK inno.N said. (Reporting by Eun-su Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [노바렉스를 움직이는 사람들]권수혜 전략기획총괄, 노바렉스 미래 그리는 지휘자
- [K-배터리 밸류업 리포트]제이오, 도전재 넘어 다각화 시동
- [이스트소프트는 지금]'알약 IPO' 특명받은 정진일 대표, 문제는 '기업가치'
- 지닥, 위믹스 많은데 '박관호 위메이드 대표 몫 못 줘'
- [탈엔비디아를 꿈꾸는 기업들]'AI 반도체 양산 임박' 모빌린트, 시험대 오른다
- [Company Watch]'애플과 멀어진' LX세미콘, DDI 대안 시급
- 외화 조달 나선 카카오, 글로벌 AI 진출 신호탄 쐈다
- [VC 투자기업]'애드테크' 버즈빌, 영업권 손상차손 93억 발생 '왜'
- [VC 투자기업]모비두, 이커머스와 매출 '윈윈' 핵심은 소스애드
- [VC 투자기업]‘전자문서 서비스’ 자버, 30억 시리즈A 나선다